959756-17-3Relevant academic research and scientific papers
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition
Reich, Siegfried H.,Sprengeler, Paul A.,Chiang, Gary G.,Appleman, James R.,Chen, Joan,Clarine, Jeff,Eam, Boreth,Ernst, Justin T.,Han, Qing,Goel, Vikas K.,Han, Edward Z. R.,Huang, Vera,Hung, Ivy N. J.,Jemison, Adrianna,Jessen, Katti A.,Molter, Jolene,Murphy, Douglas,Neal, Melissa,Parker, Gregory S.,Shaghafi, Michael,Sperry, Samuel,Staunton, Jocelyn,Stumpf, Craig R.,Thompson, Peggy A.,Tran, Chinh,Webber, Stephen E.,Wegerski, Christopher J.,Zheng, Hong,Webster, Kevin R.
, p. 3516 - 3540 (2018)
Dysregulated translation of mRNA plays a major role in tumorigenesis. Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphoryla
Novel compounds that are inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma
-
Paragraph 0608; 0611-0612, (2020/02/01)
These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
FUSED TETRAZOLES AS LRRK2 INHIBITORS
-
Page/Page column 127-128, (2019/12/04)
The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
-
Page/Page column 48, (2018/11/21)
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2
TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES
-
Page/Page column 104-105, (2008/06/13)
Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following (formula I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
